Clinical Trials Logo

Clinical Trial Summary

Objective: This study aimed to analyze the outcomes of post-infectious olfactory dysfunction treated with different doses of corticosteroids and specify factors related to the curative effect. Methods: The medical records of patients diagnosed with post-infectious olfactory dysfunction from January 2020 to december 2025 were reviewed. All patients were treated with different doses of oral corticosteroids for 12 days or they inhaled corticosteroids for 1 month.


Clinical Trial Description

All patients underwent nasal endoscopy and magnetic resonance imaging (MRI) of the olfactory pathway. At least 1 week after the symptoms such as nasal congestion and runny nose subsided, olfactory disorders did not improve. Nasal sinusitis and other lesions were excluded by physical and endoscopic examinations and imaging (sinus computed tomography and MRI), and the disorder defined as post-infectious olfactory dysfunction. All participants had a clear history of upper respiratory tract infection; other causes of olfactory disorders were excluded. All patients underwent a subjective olfactory test at the first visit and after the last treatment. The olfactory detection threshold and recognition threshold were tested using a T&T olfactory meter (Japan's First Drug Industry Co., Ltd.),which is commonly used in patients suffering from smelling disorders in asian, and correlate well with The University of Pennsylvania Smell Identification Test (UPSIT)[13]. The test was carried out according to the instructions on the olfactory meter, and the average recognition threshold of five olfactory elements was calculated to determine the degree of olfactory loss. The test results revealed normal (<1.0), mildly decreased (1.1 ≤ 2.5), moderately decreased (2.6 ≤ 4.0), severely decreased (4.1 ≤ 5.5), and complete lack of the sense of smell (> 5.5). In order to reduce the learning effects of repeated testing, all patients were order to close their eyes during the test. The patients were treated with three protocols: (1) oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days; (2) oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days; and (3) budesonide atomization suspension (AstraZeneca Trading Co., Ltd.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al[3]. A repeat T&T subjective olfactory test will be performed after the treatment. Patients with normal sense of smell will be defined as cured; patients with average T&T recognition threshold decreased by 1 point will be defined as improved; patients with average T&T recognition threshold decreased by 2 points or more, which did not reach the normal range, will be defined as significantly improved; and patients with average T&T recognition threshold decreased by 1 point, with or without falling, will be defined as invalid. SAS 9.4 software was used for statistical analysis. The treatment plan was divided into three groups, and the dependent variable was a disordered three categorical variable. The description of the numerical variables of the normal distribution adopts the mean ± standard deviation, and the analysis of variance is used for statistical analysis; the description of the numerical variables of the non-normal distribution adopts the median (interquartile range), and the rank sum test of multi-sample comparison with a completely random design is adopted conduct statistical analysis. Categorical variables are described by R*C contingency table, and the chi-square test and Fisher exact probability method are used for statistical analysis. The alpha level of the statistical test is set to 0.05. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04918953
Study type Interventional
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Hong-Gang Duan, doctor
Phone 86(China)-571-87783774
Email 2314061@zju.edu.cn
Status Not yet recruiting
Phase Phase 2
Start date June 2, 2021
Completion date December 30, 2026

See also
  Status Clinical Trial Phase
Completed NCT05268419 - Efficacy and Safety of Ethanol Inhalation on COVID-19 Treatment (a Clinical Trial Study) Phase 3
Completed NCT03251573 - The Cohort Study of Cognitive Impairment in Chinese Hemodialysis Patients
Completed NCT04238806 - Desflurane,Brain Natriuretic Peptide and Cardiac Surgery N/A
Enrolling by invitation NCT05161104 - A Multicenter Cross-sectional Study of Cardiac Ultrasound Phenotypes in Patients With Sepsis
Recruiting NCT03893136 - The Registry Study of Takayasu Arteritis in East China
Recruiting NCT03305276 - Observatory on Impact of Life Styles on Health Outcomes N/A
Recruiting NCT04963530 - Enamel Wear Evaluation in Patients With Different Ceramic Restorations N/A
Withdrawn NCT03022877 - Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions N/A
Completed NCT02041403 - RENAL RESISTIVE INDEX POST-OPERATIVE COMPLICATIONS IN MAJOR SURGERY? N/A
Withdrawn NCT01356446 - Checklist Application and Mortality N/A
Withdrawn NCT01343069 - Safety Improvement and Checklist Application N/A
Completed NCT03765372 - Evaluation of BIomarkers for POstoperative Complications in Non-cardiac Surgery Patients
Completed NCT05133960 - The Turkish Version of the Activity Diversity Questionnaire
Completed NCT03247049 - Prognosis in Intracerebral Hemorrhage. The ICHCat Score in Primary Care. N/A
Recruiting NCT03143595 - Clinical Outcomes in Elderly Patients With Preoperative Cognitive Dysfunction N/A
Not yet recruiting NCT06087939 - Outcome and Predictors of Mortality of Patients on Prolonged Mechanical Ventilation
Recruiting NCT01755819 - Outcome and Tunnel Widening After ACL Reconstruction: Comparison of Aperture and Cortical Fixation N/A
Recruiting NCT04979741 - Recovery After Intensive Care Study
Completed NCT05976204 - Prognostic Value of NLR, TLR, and ALC in Predicting ToF Primary Repair Outcome
Completed NCT04746326 - Treatment in Right Colon Diverticulitis Patients N/A